Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

May 24, 1999

(Blacksburg, Va., May 24, 1999) Jason Todd of Newport News, Va., earned a patent for his Ph.D. degree research even before receiving his degree in wood science from Virginia Tech.

Todd's dissertation research has resulted in a new, low-cost material for purifying proteins, such as to capture antibodies from blood serum or cell cultures. Such antibodies are used in diagnosis and treatment of diseases, as well as testing for drug abuse.

Todd, along with Wolfgang Glasser, professor of wood science in the College of Natural Resources, and Swapan Roy of LigoChem Inc., who received a patent (No. 5,770,712, June 23, 1998) for "Crosslinked hydrogel beads from chitosan," were recognized for their work by Virginia Tech Intellectual Properties, Inc. last week.

Chitosan is a modified form of chitin, a structural component in crab and shrimp shells. "So chitosan can be isolated from seafood waste," Todd explains. The material is formed into hydrogel beads, which are mostly water or "a highly swollen polymer network" and used in pharmaceutical separation processes. The beads are coated with "chemical functional groups" or "ligands" that grab or attract the target proteins such as antibodies or antigens.

Chitosan beads are not new. Neither is the process of using beads in separation. "The ligand is a group of atoms that interacts with the target molecule, resulting in attraction. A positively-charged ligand will attract a negatively-charged protein, for example, since opposite charges attract. Other types of interactions, such as hydrophobic interactions, can be used as well.," says Todd.

"The basis of the patent is the way we attach the ligand to the beads," he says. "We use a spacer arm to separate the ligand from the chitosan molecule. Having the space between the ligand and the supporting chitosan chain results in better selectivity -- better control in terms of getting the proteins you want to stick to your molecular structure without getting the ones you don't want. The flexible spacer gives the ligand more space in which to interact with the protein."

So far, Virginia Tech Intellectual Properties, Inc. has licensed the technology to LigoChem, a start-up company in Fairfield, N.J. "LigoChem has selected an affinity ligand that allows them to purify antibodies as well or better than present technology at lower cost," says Todd.

Why was a wood science and forest products major doing research with seafood waste? NOT because of growing up in York County near the Chesapeake Bay and being aware of the abundance of seafood byproducts, Todd admits.

"In high school I did well in chemistry, science, and math. The job prospects in engineering looked good, so I went into chemical engineering. But, when I was a senior, my friend Jim Sealey, a graduate student working with Dr. Glasser, told me he was doing interesting work with biomass.

"Much of Dr. Glasser's research is similar to what someone in materials science, chemical engineering, or chemistry might be doing," Todd says. "The only difference is that his students work exclusively with naturally-occurring materials. My work in wood science is a natural progression from my undergraduate education in chemical engineering."

Todd says he thought a career in research would be more fulfilling than the jobs available to chemical engineering bachelor-level graduates, "So I decided to go to graduate school to learn how to be a researcher. It was really Dr. Glasser's personality that attracted me into his research group."

Glasser was working with cellulose. So Todd did his masters on reactions of cellulose in solution. "We learned of some limitations of cellulose gel beads that we hypothesized could be avoided by working with chitin, a close cousin of cellulose," says Glasser. "What cellulose is to trees chitin is to marine organisms; they are chemically very similar."

"Cellulose solutions can be used to make beads," Todd explains. However, "cellulose does not dissolve in ordinary solvents. The solvent used was toxic, corrosive, and expensive mixture."

Other graduate students in Glasser's group were investigating chitosan. "It also can be solidified from solution droplets to make spherical beads, with the major attraction that it can be dissolved in mixtures of water and acetic acid -- essentially strong vinegar," says Todd. "It's a much more user-friendly solvent." Chitosan also has other properties that give chitosan beads certain advantages over cellulose beads, including greater ease of attachment of ligands.

Todd was looking for a project for his Ph.D. "The chitosan bead project seemed interesting, since it would allow me to combine elements of chemistry, chemical engineering, and materials science in my research," he says. "Plus there was funding available for the project -- an important consideration."

When he's not doing research, Todd likes mountain biking. "That's the forestry connection," he says. "I'm occasionally at one with the trees." He is also interested in music. He played the saxophone in the Tabb High School band and took up with local rock bands when he started college, playing bass guitar. Most recently, he played with the still active Blacksburg area rock band "Visible Shivers" -- but quit to finish his dissertation. "It was hard to justify travelling out of town and staying up all night."

When he gets his Ph.D. this summer, Todd hopes to continue his research in the polymer science field or in forest products.

Glasser, who has produced and patented a number of cellulose-based separation materials in the past decade, including with other graduate students, is continuing to develop and patent chitosan-based materials and products.
PR CONTACT: Susan Trulove, 540-231-5646,

Photo - of Jason Todd in lab with chitosan beads - available using FETCH:
Open FETCH on internet program.
Enter our number/address ( Come in as a guest, click on the appropriate item and choose GET FILE.

For PC's using FETCH or other FTP software:
  1. Enter our host number/address
  2. Choose anonymous for user ID
  3. Leave password blank
  4. Leave directory blank
  5. Hit OK button
Problems? Call the photo lab at 540-231-6993

Virginia Tech

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to